offline
Johnson & Johnson (JNJ) Q3 Earnings Beat Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.60 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.20 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 9.70%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.28 per share when it actually produced earnings of $2.48, delivering a surprise of 8.77%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Johnson & Johnson, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $23.34 billion for the quarter ended September 2021, missing the Zacks Consensus Estimate by 1.21%. This compares to year-ago revenues of $21.08 billion.
...
https://finance.yahoo.com/news/johnson-j...11426.html
![[Bild: JNJd035203647i.png]](https://finviz.com/publish/102121/JNJd035203647i.png)
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.60 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.20 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 9.70%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.28 per share when it actually produced earnings of $2.48, delivering a surprise of 8.77%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Johnson & Johnson, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $23.34 billion for the quarter ended September 2021, missing the Zacks Consensus Estimate by 1.21%. This compares to year-ago revenues of $21.08 billion.
...
https://finance.yahoo.com/news/johnson-j...11426.html
__________________
